|
BlueRock Therapeutics – exPDite-2 Study for Parkinson's disease - exPDite-2 is a double- blind, simulated surgery-controlled phase 3 study evaluating the potential efficacy and safety of an investigational cell therapy called bemdaneprocel designed to potentially replace the dopamine-producing neurons that are lost in Parkinson’s disease with the aim of engrafting (meaning integrate) into the brain to restore dopaminergic function. Find out if you or someone you know, is eligible for the study - exPDite-2 Study Checklist – BlueRock Therapeutics (It’s my understanding, if you’ve had DBS, you are not eligible for this study) ********** Cell therapies for Parkinson’s: How far have we come Join the World Parkinson Coalition for a special live webinar looking at dopamine cell therapies for Parkinson’s, learn about progress that has been made in this therapeutic space and the implications for people with Parkinson’s. This 75-minute webinar to look at cellular therapies and Parkinson’s and will focus on how far we’ve come in our research, clinical translation and understanding of cell therapies for Parkinson’s. The presentation and discussion will focus on progress and implications for people with Parkinson’s, including where research and clinical care is going with these types of therapies. We will also highlight the patient experience by hearing from a person who has who has had such a cell therapy ********** Impulse Control | Parkinson's Foundation For people with Parkinson’s disease (PD), managing the disease often comes down to a daily balance of dopamine — the neurotransmitter that is lost in PD. The challenge is to work with dopamine replacement therapies to find the right levels. Dopamine medications have improved life for millions of people, but researchers believe that some people with PD using these medications can develop impulse control disorders (ICDs) — unhealthy levels of gambling, shopping, eating and sexual activity.
|
